Julie Gosper, Managing Director, Rare and Specialty, Sciensus, leads the strategy, commercial execution and operational delivery of the company’s fastest-growing business segment. She is responsible for advancing Sciensus’ integrated rare disease and specialty medicines offering, which spans early access programmes, licensing, distribution, in-home clinical care and in-market patient support. With Julie’s guidance, Sciensus is committed to be the preferred partner to help global biotech companies design, launch and scale rare and ultra-rare disease product launches across Europe.
Julie focuses on widening Sciensus’ pipeline of partnerships, particularly with biotech companies preparing for European launches. She leverages the company’s proven model that combines distribution, patient support and real-world evidence to deliver to patients, faster, accelerating access to life-changing therapies for underserved patient populations. Julie observes that “Sciensus is committed to improving the healthcare journey and treatment outcomes for patients living with rare diseases”.
With 20 years of global experience, she brings deep expertise in shaping commercial pathways, unlocking market entry in demanding markets and guiding therapies from early access to full launch across Europe’s complex healthcare landscape.
Julie joins Sciensus from Clinigen, where she served as Senior Vice President for Europe, the US and rest of world with responsibility for commercial strategy, market expansion, brand lifecycle management and product partnerships. Earlier roles include leadership positions in portfolio strategy, unlicensed medicines and global partnering across multiple markets. Her career has been built around enabling availability of specialised and often hard-to-reach medicines, with particular focus on underserved patient populations.
Trained as a clinical pharmacist, Julie combines frontline clinical insight with hands-on commercial leadership developed across Europe, the US and Asia Pacific.